Filtered By:
Specialty: Cardiology
Drug: Beta-Blockers

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 184 results found since Jan 2013.

Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research

Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand.
CONCLUSIONS: The five-drugs comprising OMT were associated with a reduction in all-cause mortality and MACE in patients with ACS. Nevertheless, OMT prescribing remains underused and could be enhanced in the real-world setting. PMID: 33455848 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - January 14, 2021 Category: Cardiology Authors: Wongsalap Y, Kengkla K, Poolpun D, Saokaew S Tags: J Cardiol Source Type: research

Effect of non-adherence of evidence-based medication prescribing on major adverse cardiovascular events among acute coronary syndrome patients
Background and Aims: Combination therapy with evidence-based medicines, including 4 groups of medication: dual antiplatelet, beta-blocker, ACEI /ARB, and statin, could reduce the risk of morbidity and mortality among patients with the acute coronary syndrome (ACS). This retrospective cohort study aimed to compare the risk of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, unstable angina, and stroke during the first year of discharge between ACS patients received 4 groups and those did not receive at least 1 medication group.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: S. Chinwong, M. Chommontha, S. Kammanat, A. Phrommintikul, D. Chinwong Source Type: research

Statins and beta blockers - The most frequently encountered potential prescribing omissions in rural Romanian elderly population
Background and Aims: Cardiovascular diseases (ischaemic heart diseases and stroke) are the leading cause of death in Romania, the death rate of ischaemic heart disease being three times higher than in European Union. The aim of this study was to identify potential prescribing omissions (PPOs) and to determine their prevalence based on the STOPP / START v.2, 2015, criteria for patients over the age of 65 years old.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: V.O. Buda, O. Dalleur, A. Prelipcean, S. Buda, M. Andor, D.E. Baibata, A. Dohou, L. Petrescu, C. Cristescu Source Type: research

Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials
Conclusion: Compared with other antihypertensive agents, beta-blockers appear to be substantially less protective against stroke and overall mortality. However, they exhibit a substantial risk-reducing ability for all events when prescribed to lower BP in patients with modest or more clear BP elevations, and therefore can be used as additional agents in hypertensive patients.
Source: Journal of Hypertension - August 13, 2020 Category: Cardiology Tags: REVIEWS AND META-ANALYSES Source Type: research

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients wi...
Source: Critical Pathways in Cardiology - May 16, 2020 Category: Cardiology Tags: Review Article Source Type: research

Is Arterial Stiffness a Determinant of Hypotension?
ConclusionsHypotension is a quite common phenomenon in older subjects. Its prevention requires a more accurate management of hypertension aimed at better identifying which older subjects in whom intensive BP control may be harmful and those who may benefit from it.
Source: High Blood Pressure and Cardiovascular Prevention - May 7, 2020 Category: Cardiology Source Type: research

Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database.
CONCLUSIONS: Prescription of beta blocker in patients with AMI after PCI was sequentially increased. Continuous regular use of beta blocker for 2 years after AMI reduced major adverse events compared to no use of beta blocker. PMID: 32096355 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - February 27, 2020 Category: Cardiology Tags: Korean Circ J Source Type: research

Blood Pressure at Six Months after Acute Myocardial Infarction and Outcomes at Two Years: The Perils Associated with Excessively Low Blood Pressures
ConclusionsLow blood pressure achieved with beta-blocker and renin-angiotensin-aldosterone blocker at 6-month was associated with an increased risk of all-cause mortality independently of confounding factors in patients with AMI. This finding suggests that caution should be taken for patients with AMI who use blood pressure-lowering treatments.
Source: Canadian Journal of Cardiology - February 9, 2020 Category: Cardiology Source Type: research